Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Defence Therapeutics Inc (CSE: DTC ) 0.6300 +0.0200 (+3.28%) Official Closing Price Updated: 3:33 PM EDT, Oct 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 51,700 Open 0.6200 Bid (Size) 0.6100 (10,000) Ask (Size) 0.6600 (2,000) Prev. Close 0.6100 Today's Range 0.6200 - 0.6500 52wk Range 0.4800 - 2.990 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Precision Medicine Helps Conquer Advanced-Stage Cancer November 14, 2023 As North America reports a dramatic rise in advanced-stage cancer cases, experts are saying that major breakthroughs in oncology could make “now the best time in human history to get cancer.” According... Via PressReach Defence’s Successful Submission of an Investigational New Drug (IND) Application for AccuTOX(R) as an Injectable Anticancer Treatment for Solid Tumors November 14, 2023 (November 14, 2023) - Defence Therapeutics Inc. (CSE:DTC) (OTC Pink:DTCFF) (FSE:DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in Via PressReach Exposures Product Safety Performance YTD -73.08% -73.08% 1 Month +26.00% +26.00% 3 Month -29.21% -29.21% 6 Month -56.55% -56.55% 1 Year -77.09% -77.09% More News Read More Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030 November 14, 2023 Via FinancialNewsMedia Defence Therapeutics Key Platform Patent Accepted Broadly Covering Vaccine Technology November 07, 2023 Via PressReach Topics Intellectual Property Exposures Intellectual Property Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030 October 25, 2023 Via FinancialNewsMedia Defence’s Novel Accutox(TM) Continues to Surprise on Results Against Cancer October 18, 2023 Via PressReach Exposures Product Safety Bristol Myers Squibb Enters the Multi-Billion-Dollar Oncology Race October 17, 2023 Via PressReach Bristol Myers Squibb Joins Big Pharma’s Race to Dominate Oncology October 17, 2023 Via PressReach Defence’s Delivery of Encapsulated AccuTOX(TM)-Chitosan Nanoparticles Triggers Complete Tumor Regression in Animals with Pre-Established Solid Lymphoma October 17, 2023 Via PressReach Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology Race October 10, 2023 Via PressReach Big Pharma’s Billion-Dollar Bets on Advanced Cancer Therapies October 10, 2023 Via PressReach Exposures COVID-19 Defence Announces Peer-reviewed Publication of Its Preclinical Data on Accum(R) as an Anti-Cancer Molecule in the Journal of Cancer Science October 10, 2023 Via PressReach Defence’s Accum(R)-mRNA Lipid Nanoparticles Elicit Antibody Response 2X Stronger than Standard mRNA Vaccines September 26, 2023 Via PressReach BTV Investor Alert - Defence Therapeutics: Developing Immune-Related Therapies for Cancer Treatment May 10, 2023 Via Newsfile BTV Features: Champion Iron Limited, Defence Therapeutics, Nouveau Monde Graphite, Talisker Resources, Osisko Development & more on FOX Business News May 04, 2023 Via Newsfile Topics Supply Chain Exposures Supply Chain BTV Features: Defence Therapeutics, Volatus Aerospace, NGEx Minerals, York Harbour Metals, & AuTECO Minerals November 10, 2022 Via Newsfile Defence Therapeutics Is Granted Patents in Japan and Israel Expanding Its Novel ADC Platform Technology in the Fast Growing Antibody-Drug Conjugates Market September 29, 2022 Via Newsfile Topics Death Intellectual Property Exposures Death Intellectual Property Breakthrough Results with Accum(TM) A1-Reprogrammed MSC, Mesenchymal Stem Cells, in a Novel Vaccine Cured 80% of Animals with Pre-Established Lymphoma September 21, 2022 Via Newsfile Defence Therapeutics Applauds United States President Biden Cancer Moonshot Initiative September 16, 2022 Via Newsfile The Antibody Response Induced by Defence Therapeutics AccuVAC-PT001 Vaccine Cross-Reacts with All Tested SARS-CoV-2 Variants July 06, 2021 Via Newsfile Exposures COVID-19 Defence Therapeutics Signs a Collaboration Agreement with the Curie Institute for Testing the Accum-T-DM1 ADC Therapeutic in PDX Models of Breast Cancer June 29, 2021 Via Newsfile Defence Therapeutics AccuTOX Exhibits Potent Anti-Cancer Properties June 22, 2021 Via Newsfile Defence Therapeutics Retains the HUS Comprehensive Cancer Center to Optimize Its Accum-T-DM1 ADC Therapeutic June 07, 2021 Via Newsfile Exposures Product Safety RETRANSMISSION: Defence Therapeutics Advances in Pre-Clinical Testing of Its Infectious Disease Vaccine Program June 01, 2021 Via Newsfile Exposures COVID-19 Defence Therapeutics Advances in Pre-Clinical Testing of Its Infectious Disease Vaccine Program May 31, 2021 Via Newsfile Exposures COVID-19 Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.